$SEER

SEER Looks 5.8% Undervalued on GF Value™

Seer Inc (SEER) shareholders Bradley Radoff and Michael Torok, owning 7.7% of shares, called for board member Meeta Gulyani's resignation, citing her lack of experience and governance engagement. The company's market cap fell over 90% since her appointment. Seer's P/S ratio is 7.92, below its historical median of 9.34, and its GF Score™ is 54/100, indicating mixed fundamentals. Insiders sold shares, while institutional ownership remains stable.

Original reporting
Published Sep 4, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 2:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SEER
Neutral
medium confidence
Mentioned
$SEER
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

Activist letter introduces governance risk but no immediate financial transaction; potential for short-term volatility.

02

Market read

Governance activism may trigger modest price movement; broader market impact is minimal.

03

What to watch

Insider selling and weak profitability already signal downside; governance issue adds marginal risk.

Relevance 4/10Novelty 4/10Timing: September 04, 2026 (same-day activist letter)

Background

SEER is a biotech firm developing proteomic analysis tools, currently loss-making with negative cash flow and a market cap of ~$107 million.

Company-level read

Ticker impact

$SEERNeutralMedium confidence
Context

Shareholders Bradley Radoff and Michael Torok (7.7% stake) publicly demanded board member Meeta Gulyani resign, highlighting governance concerns amid a 90% market cap decline.

Expected impact

Modest downside risk if resignation is not achieved; possible short-term rally if board responds positively.

Evidence & confidence

Activist pressure on a small-cap biotech often leads to heightened scrutiny and short-term price moves, but no concrete transaction or financial impact is disclosed.

Market effects

Governance concerns may prompt investors to reassess risk in small-cap biotech sector.

Limited to U.S. listed biotech investors.

Low; primarily affects SEER shareholders.

Counterpoint

Board resignation demand may be overblown; company could benefit from stability if Gulyani remains.

Key entities

  • Seer Inc

    NASDAQ‑listed biotech developing proteomic tools.

  • Meeta Gulyani

    Target of resignation demand.

  • Bradley Radoff

    7.7% owner calling for board change.

  • Michael Torok

    Co‑owner of 7.7% stake.

Related articles

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

$SEERMedAI 8/10

Seer, Inc. (SEER): Results of Operations and Financial Condition

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial r

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.